CVS Health Corporation (NYSE:CVS) is one of the most undervalued blue chip stocks to buy now. Bernstein Raises PT on CVS Health (CVS) to $91, Reiterates ‘Market Perform’ Rating On January 6, 2026, Bernstein increased its price target on CVS Health Corporation (NYSE:CVS) from $87 to $91, while reiterating a ‘Market Perform’ rating. The investment firm expects a broader inflection in the government-managed care organization (MCO) sector beginning in 2026. The firm projects short-term earnings recovery, dri ...